Inspire Medical Systems, Inc.
No SEC Form 4 filings for $INSP in the last 30 days.
Deutsche Bank upgraded Palantir (PLTR) to Buy, keeping a $200 target, citing an “exceptional” Q2. Oppenheimer upgraded Inspire Medical (INSP) to Outperform with an $85 target. UBS upgraded BBB Foods (TBBB) to Buy, $51 target. Several others were upgraded or downgraded ahead of earnings or on guidance, including Walmart (WMT) to Perform and Apple (AAPL) to Hold.
Investing.com says Q2 earnings season lifted US stocks, with the S&P 500 recording a record close and the Dow topping 54,000. It highlights AI-selected picks and cites recent results for Gartner (IT), Inspire (INSP), Arm (ARM), First Solar (FSLR), and Intel (INTC), including EPS and revenue beats and raised guidance, plus valuation and margin metrics for Gartner and Arm.
Investing.com reports Q2 earnings season shows 87% of S&P 500 firms beating EPS estimates and 77% beating revenue, with blended earnings growth at 47.4% YoY. It highlights Inspire Medical Systems, saying it reported $200.6M revenue and adjusted EPS of $0.14 versus a $0.24 loss forecast, and raised 2026 revenue guidance to $835M–$875M.
Over the past 7 days, alphai's AI scored 7 news stories mentioning INSP (Inspire Medical Systems, Inc.). Coverage has skewed bullish: 7 bullish, 0 neutral, and 0 bearish.
Recent INSP coverage spans earnings, financial news and sector analysis.
Analyst upgrade tied to a specific revenue beat can attract incremental buyers ahead of subsequent catalysts.
A large EPS surprise and revenue beat point to stronger fundamentals than the market priced.
The earnings beat plus raised 2026 revenue guidance and Project Horizon restructuring are likely to sustain upward repricing, at least near-term.
The earnings beat plus higher guidance and a new restructuring and supply-chain consolidation plan likely supports near-term upside momentum, but also raises execution risk.
Raised guidance after an earnings beat supports a bullish repricing, with near-term focus on whether the new FY range holds through coding and reimbursement changes.
alphai scores every news story that mentions INSP with an AI model for sentiment and relevance, and aggregates insider trades from Inspire Medical Systems, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Deutsche Bank upgraded Palantir (PLTR) to Buy, keeping a $200 target, citing an “exceptional” Q2. Oppenheimer upgraded Inspire Medical (INSP) to Outperform with an $85 target. UBS upgraded BBB Foods (TBBB) to Buy, $51 target. Several others were upgraded or downgraded ahead of earnings or on guidance, including Walmart (WMT) to Perform and Apple (AAPL) to Hold.
3 min readInvesting.com says Q2 earnings season lifted US stocks, with the S&P 500 recording a record close and the Dow topping 54,000. It highlights AI-selected picks and cites recent results for Gartner (IT), Inspire (INSP), Arm (ARM), First Solar (FSLR), and Intel (INTC), including EPS and revenue beats and raised guidance, plus valuation and margin metrics for Gartner and Arm.
7 min readInvesting.com reports Q2 earnings season shows 87% of S&P 500 firms beating EPS estimates and 77% beating revenue, with blended earnings growth at 47.4% YoY. It highlights Inspire Medical Systems, saying it reported $200.6M revenue and adjusted EPS of $0.14 versus a $0.24 loss forecast, and raised 2026 revenue guidance to $835M–$875M.
4 min readInspire Medical Systems (INSP) shares rose 18.3% after the company reported a “beat and raise” quarter and announced a restructuring initiative. Revenue was $200.6M vs $194.7M consensus, adjusted EPS was $0.14 vs a $0.25 loss expected, and adjusted EBITDA was $38.9M. Full-year revenue guidance midpoint rose to $855M and adjusted EPS to $1.25. Oppenheimer upgraded to Outperform with an $85 target.
4 min readInspire Medical Systems reported Q2 EPS of 14 cents, versus a consensus loss of 27 cents, and sales of $200.581 million versus $194.671 million. The company raised FY2026 adjusted EPS guidance to $1.05-$1.45 and sales guidance to $835 million-$875 million. Shares rose 14.6% premarket to $59.85, and analysts at Baird and Piper Sandler lifted price targets.
3 min readInspire Medical Systems (INSP) reported Q2 revenue of $200.6M, down from $217.1M a year earlier, but returned to profit with net earnings of $0.3M versus a $3.6M loss. EPS was $0.01 versus -$0.12. For FY2026, it raised revenue guidance to $835M-$875M and expects adjusted operating margin of 4%-6% and EPS of -$0.42 to $0.17.
2 min readInspire Medical Systems (NYSE:INSP) reported Q2 CY2026 revenue of $200.6 million, down 7.6% year over year but above market expectations by 3%. Full-year revenue guidance is $855 million at the midpoint, 1.4% above estimates. Non-GAAP EPS was $0.14, above consensus. Shares rose 13.6% to $59.28 after the release.
4 min readInspire Medical Systems (INSP) said Michael H. Carrel will join its board effective July 20. Carrel is a medical device executive who previously led AtriCure (ATRC) as CEO and director, and served as Axonics board chair until its 2024 sale to Boston Scientific. Inspire develops minimally invasive OSA therapies.
2 min readUBS initiated coverage of four U.S. medtech firms. It assigned Buy ratings to Intuitive Surgical (ISRG) with a $500 price target and Enovis (ENOV) with a $51 target, citing growth drivers and improving fundamentals. UBS gave Inspire Medical Systems (INSP) a Sell rating with a $39 target and Integra LifeSciences (IART) a Neutral rating with a $19 target, citing competition, reimbursement and limited catalysts.
4 min readInspire Medical Systems, Inc. (INSP) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. insp-20260720 0001609550 False 0001609550 2026-07-20 2026-07-20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _________________________ FORM 8-K _________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 19
2 min read
